This is a snippet of the transcript, sign up to read more.
I believe this will continue throughout the year because one of the major players, Cuervo, is still using their own agaves. According to the latest report I saw from them, their biological assets suggest they can produce almost 60 million liters of Tequila this year. Last year, they sold approximately 95 million liters. So, they can produce more than half of this year's requirements. They're using their own agave and buying less agave at a lower price. The supply of agave is currently very high. Therefore, I think the price will stay between 15 to 18 pesos for the rest of the year. There might be a slight increase in November and December due to the end of the rainy season when other distilleries could start their production. However, I don't think the price will exceed 20 pesos. It will likely be between 15 and 18.
This is a snippet of the transcript, sign up to read more.
I've been in talks with some agave producers because I also need agaves for production. They are now open to making long-term contracts, typically for five or six years, which is the normal cycle of the agaves. They are considering offering a fixed price, not a different price for each year. They haven't mentioned the price yet, but I think it will be around 14 pesos.
This is a snippet of the transcript, sign up to read more.
Yes, the spot market price could indeed go lower. Just a few hours ago, I was looking at the latest inventory report from the CRT. As of the end of June, there were 1.375 billion agave plants. The largest quantities are from the years 2020, 2021, and 2022. With the current agave inventory, we have enough to produce Tequila for between 13 and 18 years, given the current agave plantations.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research